Tvardi Therapeutics, Inc.
No enriched coverage for $TVRD in the last 7 days.
No SEC Form 4 filings for $TVRD in the last 30 days.
See all $TVRD insider activity →Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immu
Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for its oral STAT3 inhibitor TTI-109. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60% in exploratory analyses. It also cited shorter diarrhea duration vs TTI-101. TVRD shares rose sharply on the news.
Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug. The company said TTI-109 converted to TTI-101 within two hours, showed dose-proportional pharmacokinetics and target engagement, and had diarrhea events comparable to placebo (0.46 vs 3.35 days vs near-equivalent TTI-101). Shares rose ~49.75% to $3.01; plans to advance into dermatologic and gastrointestinal indications pending IND clearance and funding.
Recent TVRD coverage spans earnings, financial news and technology.
Positive early pharmacodynamic and tolerability signals for TTI-109 in healthy volunteers, with UC selected as the initial indication and a defined next catalyst (Aug 19 webinar).
Positive Phase 1 pharmacology/tolerability readout for TTI-109 supports advancing into Phase 2 and can sustain momentum after a large same-day gain.
Positive early clinical pharmacology/safety read-through for TTI-109 supports advancing into dermatology and gastrointestinal indications, driving a sharp move.
The article reports a same-day clinical-trial readout for TTI-109 that is driving a sharp premarket/early-session rally in TVRD.
Phase 1 pharmacology/tolerability data for TTI-109 strengthens the rationale to advance into Phase 2, but remains pre-IND/early-stage with funding/IND gating.
alphai scores every news story that mentions TVRD with an AI model for sentiment and relevance, and aggregates insider trades from Tvardi Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immu
4 min readTvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for its oral STAT3 inhibitor TTI-109. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60% in exploratory analyses. It also cited shorter diarrhea duration vs TTI-101. TVRD shares rose sharply on the news.
4 min readTvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug. The company said TTI-109 converted to TTI-101 within two hours, showed dose-proportional pharmacokinetics and target engagement, and had diarrhea events comparable to placebo (0.46 vs 3.35 days vs near-equivalent TTI-101). Shares rose ~49.75% to $3.01; plans to advance into dermatologic and gastrointestinal indications pending IND clearance and funding.
4 min readTvardi Therapeutics (TVRD) shares rose about 42% after the company reported Phase 1 results for TTI-109, its next-generation STAT3 inhibitor, citing improved tolerability and target engagement. The stock was about $2.885 on Nasdaq, up 42.04%, after opening at $2.16 and reaching $3.01.
2 min readTvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug of TTI-101. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional PK with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60%. It plans to advance TTI-109 into dermatologic and GI diseases pending IND clearance and funding; webcast July 7, 8:30am ET.
4 min readBiotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.
6 min readTvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001346830 0001346830 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readTvardi (TVRD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
3 min readThe heavy selling pressure might have exhausted for Tvardi (TVRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
3 min readTvardi Therapeutics Inc. ( NASDAQ:TVRD ) stock is falling on Monday with a session volume of 5.56 million versus the average volume of 42.08 thousand, as per data from Benzinga Pro.
3 min read
